Study on IgG Allotypes and Anti-Adalimumab Antibodies
Author Information
Author(s): Bartelds Geertje M, de Groot Els, Nurmohamed Michael T, Hart Margreet HL, van Eede Peter H, Wijbrandts Carla A, Crusius Jakob BA, Dijkmans Ben AC, Tak Paul Peter, Aarden Lucien, Wolbink Gerrit J
Primary Institution: Jan van Breemen Institute
Hypothesis
Is there an association between IgG allotype mismatch and the development of anti-adalimumab antibodies in treated rheumatoid arthritis patients?
Conclusion
The study found that an allotype mismatch did not lead to a higher frequency of anti-adalimumab antibodies; instead, patients with the same allotype as adalimumab had a higher frequency of these antibodies.
Supporting Evidence
- 39 out of 249 patients had anti-adalimumab antibodies (16%).
- Patients homozygous for G1m17 had the highest frequency of anti-adalimumab antibodies (41%).
- No anti-allotype antibodies against adalimumab were detected.
Takeaway
The study looked at whether differences in certain proteins in the blood could cause patients to develop antibodies against a treatment drug, but found that having the same protein type as the drug actually led to more antibodies.
Methodology
This cohort study involved 250 rheumatoid arthritis patients treated with adalimumab, measuring IgG allotypes and anti-adalimumab antibodies using various assays.
Limitations
The study did not detect anti-allotype antibodies, which may limit the conclusions about immunogenicity.
Participant Demographics
{"age":"52 ± 13","female_percentage":79,"prior_DMARDs":"3.4 ± 1.6","methotrexate_use_percentage":80,"prednisone_use_percentage":33,"disease_duration":"8 (4 to 17)"}
Statistical Information
P-Value
0.0001
Confidence Interval
95% CI = 1.608 to 4.332
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website